Search research articles
Contact Us
Filters
Showing results (1-10 of 22) with videos related to
Page
of 3
Sort By:
Journal of Medical Economics
|
September 6, 2013
Economic burden of selected adverse events in patients aged ≥65 years with metastatic renal cell carcinoma
May Hagiwara, Michelle D Hackshaw, Gerry Oster
Clinicoeconomics and Outcomes Research : CEOR
|
July 4, 2012
Retrospective US database analysis of drug utilization patterns, health care resource use, and costs associated with adjuvant interferon alfa-2b therapy for treatment of malignant melanoma following surgery
Michelle D Hackshaw, Arun Krishna, David J Mauro
Journal of Managed Care & Specialty Pharmacy
|
November 6, 2015
The Authors Respond
Ryan N Hansen, Michelle D Hackshaw, Sean D Sullivan, et al.
Journal of Managed Care & Specialty Pharmacy
|
January 7, 2015
Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States
Thomas E Delea, Jordan Amdahl, Jose Diaz, et al.
Clinical Genitourinary Cancer
|
May 26, 2016
Prescribing Preferences in the First-Line Treatment for Patients With Metastatic Renal Cell Carcinoma in the United States
Michelle D Hackshaw, Michael Holmes, Maria Lankford, et al.
Journal of Managed Care & Specialty Pharmacy
|
May 27, 2014
Persistence and compliance with pazopanib in patients with advanced renal cell carcinoma within a U.S. administrative claims database
Michelle D Hackshaw, Saurabh P Nagar, Daniel C Parks, et al.
BMC Cancer
|
January 16, 2022
Health-related quality of life in women with breast cancer: a review of measures
Maribel Salas, Margaret Mordin, Colleen Castro, et al.
Sarcoma
|
August 13, 2016
A Systematic Literature Review of Adverse Events Associated with Systemic Treatments Used in Advanced Soft Tissue Sarcoma
Ann Colosia, Shahnaz Khan, Michelle D Hackshaw, et al.
Drugs - Real World Outcomes
|
December 20, 2022
Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Treatments After T-DM1 in the United States
Neelima Denduluri, Janet L Espirito, Michelle D Hackshaw, et al.
Journal of Managed Care & Specialty Pharmacy
|
May 27, 2015
Persistence and compliance among U.S. patients receiving pazopanib or sunitinib as first-line therapy for advanced renal cell carcinoma: a retrospective claims analysis
Stacey A DaCosta Byfield, Jeffrey T McPheeters, Tanya M Burton, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 22) with videos related to
Sort By:
Page
of 3
Journal of Medical Economics
|
September 6, 2013
Economic burden of selected adverse events in patients aged ≥65 years with metastatic renal cell carcinoma
May Hagiwara, Michelle D Hackshaw, Gerry Oster
Clinicoeconomics and Outcomes Research : CEOR
|
July 4, 2012
Retrospective US database analysis of drug utilization patterns, health care resource use, and costs associated with adjuvant interferon alfa-2b therapy for treatment of malignant melanoma following surgery
Michelle D Hackshaw, Arun Krishna, David J Mauro
Journal of Managed Care & Specialty Pharmacy
|
November 6, 2015
The Authors Respond
Ryan N Hansen, Michelle D Hackshaw, Sean D Sullivan, et al.
Journal of Managed Care & Specialty Pharmacy
|
January 7, 2015
Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States
Thomas E Delea, Jordan Amdahl, Jose Diaz, et al.
Clinical Genitourinary Cancer
|
May 26, 2016
Prescribing Preferences in the First-Line Treatment for Patients With Metastatic Renal Cell Carcinoma in the United States
Michelle D Hackshaw, Michael Holmes, Maria Lankford, et al.
Journal of Managed Care & Specialty Pharmacy
|
May 27, 2014
Persistence and compliance with pazopanib in patients with advanced renal cell carcinoma within a U.S. administrative claims database
Michelle D Hackshaw, Saurabh P Nagar, Daniel C Parks, et al.
BMC Cancer
|
January 16, 2022
Health-related quality of life in women with breast cancer: a review of measures
Maribel Salas, Margaret Mordin, Colleen Castro, et al.
Sarcoma
|
August 13, 2016
A Systematic Literature Review of Adverse Events Associated with Systemic Treatments Used in Advanced Soft Tissue Sarcoma
Ann Colosia, Shahnaz Khan, Michelle D Hackshaw, et al.
Drugs - Real World Outcomes
|
December 20, 2022
Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Treatments After T-DM1 in the United States
Neelima Denduluri, Janet L Espirito, Michelle D Hackshaw, et al.
Journal of Managed Care & Specialty Pharmacy
|
May 27, 2015
Persistence and compliance among U.S. patients receiving pazopanib or sunitinib as first-line therapy for advanced renal cell carcinoma: a retrospective claims analysis
Stacey A DaCosta Byfield, Jeffrey T McPheeters, Tanya M Burton, et al.
Page
of 3